Cathay Health Invests in Moon Surgical’s $31.3M Series A to Accelerate Development of Maestro Robotic System
June 29, 2022
Europe
New funding to accelerate development of the company’s unique co-manipulative surgical robotic system in preparation for commercial launch
Today, Cathay Health announces its recent investment in collaborative robotics pioneer Moon Surgical. The $31.3M Series A funding round was led by GT Healthcare Capital & Partners with participation from Cathay Health, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Sofinnova MD Start, as well as seasoned MedTech leaders Yann Fleureau, Sid Siddarth, Sacha Loiseau, and Richard Leparmentier.
Moon Surgical marks Cathay Health’s fourth investment since launch, following French medtech Tissium, US-based pre-clinical biotech company Kojin Therapeutics and US-based healthcare venture studio Initiate. The company will use the funding to expand its team in both France and the United States and accelerate the development of its Maestro Robotic System. As part of the transaction, Cathay Health Venture Partner Dr. Steve Oesterle will be advising the board as a unique industry expert.
Founded in Paris in 2019 and incubated by Sofinnova MD Start, Moon Surgical has shown its prowess at speed and innovation with early systems already fully functional and driven by more than thirty surgeons across two continents and multiple clinical indications. Small, adaptable, and integrated into existing clinical workflows, Maestro is designed to support surgeons and patients in the 18.8 million soft-tissue surgery procedures not currently supported by telerobotic systems.
“At Moon Surgical, our ambition is to revolutionize minimally invasive surgery through the power of collaborative and adaptive robotics. Our Maestro System can be used in any laparoscopy, in any operating room,” said Anne Osdoit, CEO of Moon Surgical. “We are excited to work with our new partners at Cathay Health, GT Healthcare and Johnson & Johnson, as we enter the next stage of our company’s evolution.”
“This is about democratizing control during surgery. Maestro provides instant, reliable, and affordable support while bolstering surgeon confidence for every patient, every intervention, everywhere,” says Dr. Steve Oesterle, Venture Partner at Cathay Health. “We’re all very eager to support this global business in its development so that it can rapidly be used in many surgeries.”
About Moon Surgical
Moon Surgical, based in Paris, France, and San Carlos, California, believes the future of the operating room lies in the hands of the empowered surgeon. By equipping surgeons with complete control, renewed confidence, and technology adaptable to any situation they encounter, Moon Surgical strives to improve efficiency in operating rooms and provide better surgical care for patients. The minimalistic, co-manipulation Maestro Robotic System uses tomorrow’s technology to deliver these vital skills to surgeons, today. www.moonsurgical.com
About Cathay Health
Cathay Health, affiliated to Cathay Capital, is a global fund investing at the convergence of healthcare, life sciences and technology. As a multi-stage €500M fund, it backs venture and growth-stage companies across Europe, North America and Asia whose tech-enabled solutions catalyze groundbreaking advances in medicine. Its global platform brings together startups, established companies and large corporations to fuel cross-border, cross-industry collaboration and growth with direct access to new markets, partners and patients. From the world’s leading life sciences and technology hubs, including San Francisco, New York, London, Cambridge, Paris, Basel and Shanghai, Cathay Health partners with future leaders in the data-driven medicine era that will transform human health and care in all its dimensions. Follow us on LinkedIn, Twitter @CathayHealth